Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled …
MA Riedl, V Grivcheva-Panovska, D Moldovan, J Baker… - The Lancet, 2017 - thelancet.com
Background Hereditary angio-oedema is a recurrent, oedematous disorder caused by
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled …
MA Riedl, V Grivcheva-Panovska, D Moldovan, J Baker… - THE LANCET, 2017 - air.unimi.it
Background Hereditary angio-oedema is a recurrent, oedematous disorder caused by
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled …
MA Riedl, V Grivcheva-Panovska, D Moldovan, J Baker… - The Lancet, 2017 - Elsevier
Background Hereditary angio-oedema is a recurrent, oedematous disorder caused by
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
[引用][C] Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled …
MA Riedl, V Grivcheva-Panovska, D Moldovan, J Baker… - The Lancet, 2017 - cir.nii.ac.jp
Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase
2, multicentre, randomised, double-blind, placebo-controlled crossover trial | CiNii Research …
2, multicentre, randomised, double-blind, placebo-controlled crossover trial | CiNii Research …
Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled …
MA Riedl, V Grivcheva-Panovska… - Lancet (London …, 2017 - europepmc.org
Background Hereditary angio-oedema is a recurrent, oedematous disorder caused by
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
[PDF][PDF] Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled …
MA Riedl, V Grivcheva-Panovska, D Moldovan, J Baker… - Lancet, 2017 - yangmedicine.com
Background Hereditary angio-oedema is a recurrent, oedematous disorder caused by
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled …
MA Riedl, V Grivcheva-Panovska… - Lancet (London …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Hereditary angio-oedema is a recurrent, oedematous disorder caused by
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled …
MA Riedl, V Grivcheva-Panovska, D Moldovan, J Baker… - The Lancet, 2017 - thelancet.com
Background Hereditary angio-oedema is a recurrent, oedematous disorder caused by
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …